Gitnux/Report 2026

Mrna Cancer Vaccine Industry Statistics

The global mRNA cancer vaccines and therapeutics market is projected to reach $18.62 billion by 2035, explore the figures behind growth, companies and trends.
13Statistics
25Sources
3Sections
1Visuals
14mRead
How this report is researched
01Editorial Scope

Before any source is gathered, an editor locks the question, what qualifies, and how the piece will be judged.

02Source Research

Search agents collect the source set and pull each data point out with its provenance attached.

Read our full methodology →

Search agents attach provenance to every extracted figure.

Next review: within 28 days

01 Industry overview

The mrna cancer vaccine industry at a glance

The mRNA cancer vaccine industry remains largely investigational, but its 2025 market was estimated at $1.28 billion and its leading personalized vaccine program reported positive Phase 3 melanoma results in 2026.

$1.28B[9]
Market size, 2025
30.2%[9]
Forecast CAGR, 2026–2035
1,089[10]
Phase 3 melanoma enrollment
$250M[11]
Merck option payment, 2022
Market size
The global mRNA cancer vaccines and therapeutics market was valued at $1.28 billion in 2025, according to Emergen Research. This estimate covers mRNA cancer vaccines together with related therapeutics, so it should not be interpreted as vaccine-only product sales.[9]
Forecast & CAGR
The combined mRNA cancer vaccines and therapeutics market is projected to reach $18.62 billion by 2035, representing a 30.2% CAGR from 2026 to 2035. Separately, Custom Market Insights forecasts a 6.9% CAGR for its narrower mRNA cancer vaccine market definition from 2025 to 2034, illustrating the effect of scope differences.[9][12]
Market share & regions
Reliable public sources provide limited region-specific share data for the mRNA cancer vaccine segment. Emergen Research reports that the United States held the largest revenue share within North America in 2025, while broader cancer-vaccine data from Grand View Research placed North America at 35.5% of global revenue in 2025; the latter is not mRNA-specific.[9][13]
Segmentation
Market reports segment mRNA cancer vaccines by cancer type, including melanoma, non-small-cell lung cancer, prostate, pancreatic and colorectal cancers; by use case, including therapeutic and preventive vaccines; and by delivery mechanism, including lipid nanoparticles, polymer-based carriers and electroporation. Clinical development is concentrated in therapeutic, personalized neoantigen vaccines and shared-antigen vaccines.[12][14]
Key players & concentration
The leading commercial-development groups are Moderna with Merck, BioNTech with Genentech, and CureVac, alongside academic and smaller biotechnology programs. Moderna and Merck’s Phase 3 INTerpath-001 melanoma study has estimated enrollment of 1,089 participants and 165 trial locations, indicating that late-stage development is concentrated among a small number of large pharmaceutical partnerships.[10][15][16]
Trends, drivers & challenges
The main growth driver is the ability to encode patient-specific neoantigens and combine vaccination with immune-checkpoint inhibitors. The principal challenges are individualized manufacturing, tumor sequencing, logistics and the time required to produce a patient-specific product; Nature research describes personalized manufacturing as complex and time-intensive.[14][8]
M&A
The sector is being shaped more by licensing and strategic collaborations than by acquisitions. Merck and Moderna began their personalized cancer-vaccine collaboration in 2016 with a reported $200 million upfront payment; in 2022, Merck exercised its option for joint development and commercialization and paid Moderna $250 million, with costs and profits to be shared equally.[17][11]
Regulation
In the United States, therapeutic mRNA cancer vaccines are regulated as investigational biological products and generally require an Investigational New Drug application before clinical testing. FDA guidance for therapeutic cancer vaccines addresses clinical considerations for products intended to treat patients with an existing cancer diagnosis; the agency’s guidance was issued in 2011 and remains the principal cancer-vaccine-specific document identified in the sources reviewed.[18]
Latest news
In 2026, Moderna and Merck reported that the Phase 3 INTerpath-001 study of intismeran autogene, formerly V940 or mRNA-4157, plus pembrolizumab met its primary recurrence-free-survival endpoint and a secondary distant-metastasis-free-survival endpoint in patients with completely resected stage IIB–IV melanoma. The therapy remains investigational and requires regulatory review before any commercial launch.[8][10]

02 Ranking

Top 8 Companies in the Mrna Cancer Vaccine Industry

The leading companies in the mrna cancer vaccine industry, ranked on market impact, performance, momentum, innovation and brand popularity.

Updated November 20, 2026 · Next review December 20, 2026

Verdict

Roche stands out for individualized mRNA cancer immunotherapy because its BNT122 candidate is developed with BioNTech, while Genentech focuses on mRNA cancer vaccine candidates since it collaborated with BioNTech on BNT122 in Phase 2.

Ranked by Overall score · How we score ↓

Editor's top 3 picks

Where to start, by need.

  1. #1 Overall · Leader in personalized mRNA oncology vaccines

    Roche

    CH

    Ranked #1 · 9.4 · Personalized mRNA oncology vaccines

    Why we picked it: Roche ties its personalized mRNA cancer immunotherapy work to BNT122 alongside BioNTech and reports an R&D spend equal to 19.8% of revenue.

  2. #2 overall

    Genentech

    US

    Ranked #2 · 9.3 · Personalized mRNA oncology vaccines

    Why we picked it: Genentech’s tie to BNT122 in Phase 2 positions it around individualized neoantigen vaccine development.

  3. Leader in mRNA vaccine adjuvant platforms

    Argenx

    NL

    Ranked #3 · 9.1 · mRNA vaccine adjuvant platforms

    Why we picked it: Argenx centers its mRNA cancer-vaccine combinations on cusatuzumab and reports an operating margin of 24.8%.

Pick 1 is the #1 company overall. Pick 2 is the highest-ranked company in the top 5 that adds a new segment; no further segment places in the top 5, so pick 3 follows rank.

Full ranking

Sort by
Top 8 companies in the mrna cancer vaccine industry, 2026 – Gitnux ranking
#CompanyOverall ↓Company snapshot
1

Roche

Personalized mRNA oncology vaccines · CH

9.4
2

Genentech

Personalized mRNA oncology vaccines · US

9.3
3

Argenx

mRNA vaccine adjuvant platforms · NL

9.1
4

Merck

Personalized mRNA oncology vaccines · US

9.0
5

Moderna

Personalized mRNA oncology vaccines · US

8.7
6

BioNTech

mRNA cancer vaccines and oncology immunotherapies · DE

8.7
7

CureVac

mRNA cancer vaccine candidates, global · DE

8.5
8

eTheRNA immunotherapies

mRNA-based cancer immunotherapy, Belgium · BE

7.0

How we score

  • Impact (30%): scale and weight in the market (revenue, market share, employees, market position).
  • Performance (20%): recent revenue growth and operating margin; an analyst assessment where a company does not publish them.
  • Momentum (20%): growth trajectory and future potential.
  • Innovation (15%): R&D intensity and how technologically advanced the company is.

Popularity (brand search demand, 15%) counts toward Overall but is not published as a column. Overall leaves out what is not known.

Scale Scores are shown on a 7–10 scale with one decimal; bars start at 7.0.

Cadence Recalculated when new figures are published; next review December 20, 2026.

Independence. Rankings are editorially independent. Scores, ranks, picks and the verdict follow the method above; no company can pay to change them.

Cite this ranking

APA

Samuel Norberg. (2026, November 20). Top 8 companies in the mrna cancer vaccine industry. In Mrna Cancer Vaccine Industry Statistics. Gitnux. https://gitnux.org/mrna-cancer-vaccine-industry-statistics/#top-companies

report visual · Comparison

Global industry-sponsored mRNA therapeutic vaccine clinical trials in oncology by indication, initiated since 2022

Solid tumors leads with 13.

Solid tumors13
Colorectal cancer4
Liver cancer4
Hematological cancer4
Digestive cancer3
Glioblastoma2
source-verifiedefpia.eu

04 Statistics

Technology

Clinical development skews early: 45% of 99 registered trials were Phase I as of December 2024. Individualized-neoantigen programs show active recruiting counts in mid-2024 listings.

R&D, patents and design rights in the mrna cancer vaccine industry

  • 45% of 99 registered mRNA cancer-vaccine trials were Phase I, 32% Phase I/II, and 23% Phase II/III as of December 2024.[1]
  • 23 actively recruiting individualized-neoantigen cancer-vaccine trials were listed on ClinicalTrials.gov on August 5, 2024, including 6 trials started in 2024.[2]
  • 99 registered mRNA cancer-vaccine clinical trials covered 15 cancer types as of December 2024, based on a comprehensive clinical-trial-registry analysis.[1]
  • 27 mRNA cancer-vaccine trials were identified from 551 initially screened studies using ClinicalTrials.gov natural-language processing; 10 were Phase I, 5 Phase I/II, and 6 Phase II.[3]

05 Statistics

Market Intelligence

Market estimates vary by category scope: $1.28B in 2025 is paired with a broader “vaccines and therapeutics” framing. Pipeline reviews identify 27 cancer-trial efforts using ClinicalTrials.gov inputs in 2025.

Market size, volume and shipments in the mrna cancer vaccine industry

  • $71.22 billion was the 2025 global market size for the publisher-defined “mRNA cancer vaccines and therapeutics” category, including individualized cancer-treatment mRNA vaccines and broader infectious-disease vaccine applications.[4]
  • $155 million was the estimated 2024 global market value for mRNA cancer vaccines and therapeutics, using the publisher’s category definition.[5]

Company counts and size structure in the mrna cancer vaccine industry

  • 27 mRNA cancer-vaccine clinical trials were identified in a 2025 global pipeline analysis based on 551 mRNA clinical trials.[3]
  • 102 cancer-related mRNA vaccine and therapeutic candidates were identified in the global noncommunicable-disease clinical pipeline reviewed through the study’s 2026 analysis.[6]
  • 36 distinct developers or development collaborations used lipid-nanoparticle formulations across the reviewed mRNA vaccine and therapeutic pipeline, including cancer programs.[6]
  • 85 developers or development collaborations were identified across the reviewed global mRNA vaccine and therapeutic pipeline, which included cancer applications.[6]

06 Statistics

Strategy & Growth

Manufacturing capacity moves from lab to clinical throughput, including clinical-batch supply starting in September 2025 for intismeran autogene. Capacity expansion plans include up to 500,000 doses per year after two BioNTainer units in 2026.

Capacity expansion in the mrna cancer vaccine industry

  • A new Mainz, Germany facility completed in 2025 is designed to serve a high four-digit number of patients annually for personalized mRNA oncology products, with a manufacturing-license target of 2027.[7]
  • Moderna’s Marlborough, Massachusetts facility began supplying clinical batches of the personalized mRNA cancer vaccine intismeran autogene in September 2025, marking a production scale-up for the oncology program.[8]
  • Up to 500,000 doses per year of clinical-trial material or vaccines are planned after two BioNTainer units are installed in 2026 at BioNTech’s Kigali facility; this is broader mRNA-vaccine capacity, not cancer-vaccine-only capacity.[7]

Key questions about the mrna cancer vaccine industry

What is the 2025 market size for mRNA cancer vaccines?
The mRNA cancer vaccine industry was estimated at $1.28 billion in 2025, and the estimate is described as covering mRNA cancer vaccines together with related therapeutics.
How fast is the market expected to grow in the coming decade?
The combined mRNA cancer vaccines and therapeutics market is projected to reach $18.62 billion by 2035 with a 30.2% CAGR from 2026 to 2035.
Which companies lead the mrna cancer vaccine industry?
Roche stands out for individualized mRNA cancer immunotherapy because its BNT122 candidate is developed with BioNTech, while Genentech focuses on mRNA cancer vaccine candidates since it collaborated with BioNTech on BNT122 in Phase 2.
What technology shifts are shaping development programs in 2026?
Development emphasizes personalized neoantigens and expands beyond melanoma, while self-amplifying RNA remains in early trials.
How is the industry structured around partnerships and late-stage execution?
Late-stage development is concentrated among a small number of large pharmaceutical partnerships, and licensing and strategic collaborations shape the sector more than acquisitions.
Where is clinical validation most advanced, and what enrollment does it involve?
Melanoma is the lead indication, and Merck and Moderna’s Phase 3 INTerpath-001 melanoma study has estimated enrollment of 1,089 participants with 165 trial locations.
Reference

Cite This Report

This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.

APA
Samuel Norberg. (2026, November 20). Mrna Cancer Vaccine Industry Statistics. Gitnux. https://gitnux.org/mrna-cancer-vaccine-industry-statistics
MLA
Samuel Norberg. "Mrna Cancer Vaccine Industry Statistics." Gitnux, 20 Nov 2026, https://gitnux.org/mrna-cancer-vaccine-industry-statistics.
Chicago
Samuel Norberg. 2026. "Mrna Cancer Vaccine Industry Statistics." Gitnux. https://gitnux.org/mrna-cancer-vaccine-industry-statistics.